November 21, 2018 — The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia…Original Article
FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia
